Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats
Rae J. Herman, Matthew R. Hayes, Janet Audrain‐McGovern, et al.
Psychopharmacology (2023) Vol. 240, Iss. 6, pp. 1373-1386
Closed Access | Times Cited: 12

Showing 12 citing articles:

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino, et al.
JAMA Psychiatry (2025)
Closed Access | Times Cited: 2
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 10
Neurobiological mechanisms of nicotine's effects on feeding and body weight
Y. Li, Jian Mao, Guobi Chai, et al.
Neuroscience & Biobehavioral Reviews (2025) Vol. 169, pp. 106021-106021
Closed Access | Times Cited: 1
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access | Times Cited: 1
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Rae J. Herman, Heath D. Schmidt
Physiology & Behavior (2024) Vol. 281, pp. 114565-114565
Open Access | Times Cited: 6
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Silvia Tempia Valenta, Alba Nicastri, Federica Perazza, et al.
Current Treatment Options in Psychiatry (2024)
Closed Access | Times Cited: 6
Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study
Tatsumi Hirotsu, Kanta Taniguchi, Rimei Nishimura
Frontiers in Clinical Diabetes and Healthcare (2025) Vol. 6
Open Access
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study
Feras Al-Moussally, Saud Khan, Vinay Katukuri, et al.
Drugs (2025)
Closed Access
Semaglutide and GLP-1 Agonists
Michael Fagiola
American Journal of Forensic Medicine & Pathology (2025)
Closed Access
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review
Serene M. L. Lee, Maggie Li, Gia Han Le, et al.
Annals of General Psychiatry (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Effect of acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, and estrus phase on cue- and drug-induced fentanyl seeking in female rats
Luke A. Urbanik, Jennifer L. Booth, Nikhil Acharya, et al.
Behavioural Pharmacology (2024)
Closed Access
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
Chenqi Lu, Cong Xu, Jun Yang
Medicina (2024) Vol. 61, Iss. 1, pp. 17-17
Open Access
Page 1

Scroll to top